Skip to main content
PMC home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1982 Aug;13(2):140–144. doi: 10.1007/BF00205315

Influence of non-specific immunologic factors on prognosis in advanced bronchogenic carcinoma

A M Liberati 1,2,3,4, J G Voelkel 1,2,3,4, E C Borden 1,2,3,4, A S Coates 1,2,3,4, D L Citrin 1,2,3,4, G T Bryan 1,2,3,4
PMCID: PMC11039203  PMID: 6961952

Abstract

Fifty-nine evaluable patients with stage III bronchogenic carcinoma, participating in a randomized clinical trial evaluating the effect of adjuvant immunotherapy with levamisole or BCG in the treatment of clinically advanced lung cancer, were studied for their immunocompetence by in vitro and in vivo assays. Immunological tests consisted of measurements of natural killer (NK) cell and killer (K) cell cytotoxicity, skin testing reactivity to recall antigens, absolute lymphocyte count, and serum immunoglobulin (Ig) levels. Pretherapy K cell cytotoxic levels, skin test reactivity to trichophyton antigen, and increased IgA levels were predictive of the overall clinical course. Despite non-specific immunotherapy, progressive decline of NK and K cell cytotoxicity occurred during the course of the disease. These findings, however, were of limited clinical value. Initial performance status and disease extent significantly influenced time to progression and survival. Little further prognostic information was obtained from the immunological tests over those provided by clinical performance status and disease extent. No statistically significant differences were found in either time to progression or survival between controls and patients receiving either levamisole or BCG.

Keywords: Natural Killer, Lymphocyte Count, Levamisole, Cell Cytotoxicity, Serum Immunoglobulin

References

  • 1.Amery WK. A placebo-controlled levamisole study in resectable lung cancer. In: Terry WD, Windhorst D, editors. Immunotherapy of cancer: Present status of trials in man. New York: Raven Press; 1978. p. 191. [Google Scholar]
  • 2.Barnes EW, Farmer A, Penhale WJ, Irvine WJ, Roscoe P, Horne NW. Phytohemagglutinin-induced lymphocyte transformation in newly presenting patients with primary carcinoma of the lung. Cancer. 1975;36:187. doi: 10.1002/1097-0142(197507)36:1<187::aid-cncr2820360117>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  • 3.Brugarolas A, Han T, Takita H, Minowada J. Immunologic assays in lung cancer. Skin tests, lymphocyte blastogenesis, and rosette-forming cell count. NY State J Med. 1973;73:747. [PubMed] [Google Scholar]
  • 4.Cannon GB, Dean JH, Herberman RB, Perlin E, Reid J, Miller C, Lang NP. Association of depressed postoperative lymphoproliferative responses to alloantigens with poor prognosis in patients with stage I lung cancer. Int J Cancer. 1980;25:9. doi: 10.1002/ijc.2910250103. [DOI] [PubMed] [Google Scholar]
  • 5.Catalona WJ, Sample WF, Chretien PB. Lymphocyte reactivity in cancer patients: correlation with tumor histology and clinical stage. Cancer. 1973;31:65. doi: 10.1002/1097-0142(197301)31:1<65::aid-cncr2820310109>3.0.co;2-y. [DOI] [PubMed] [Google Scholar]
  • 6.Coates AS, Klopp RG, Zarling JM, Borden EC, Crowley JJ, Carbone PP. Immunologic function during adjuvant BCG immunotherapy for malignant melanoma: induction of anergy. Cancer Immunol Immunother. 1979;7:175. [Google Scholar]
  • 7.Crowley J. Some extensions of the logrank test. Wisconsin Clinical Cancer Center, Biostatistics and Technical Reports. 1980;10:11. [Google Scholar]
  • 8.Dalbow MH, Concannon JP, Eng CP, Wfil CS, Conway J, Nambisan PTN. Lymphocyte mitogen stimulation studies for patients with lung cancer: evaluation of prognostic significance of preirradiation therapy studies. J Lab Clin Med. 1977;90:295. [PubMed] [Google Scholar]
  • 9.DiBella NJ, Brown GL. Immunologic dysfunction in the myeloproliferative disorders. Cancer. 1978;42:149. doi: 10.1002/1097-0142(197807)42:1<149::aid-cncr2820420125>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
  • 10.Faguet GB. Quantitation of immunocompetence in Hodgkin's disease. J Clin Invest. 1975;56:951. doi: 10.1172/JCI108175. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Forbes JT, Greco FA, Oldham RK. Human natural cell-mediated cytotoxicity. II. Levels in neoplastic disease. Cancer Immunol Immunotherapy. 1981;11:147. [Google Scholar]
  • 12.Golub SH, O'Connell TX, Morton DL. Correlation of in vivo and in vitro assays of immunocompetence in cancer patients. Cancer Res. 1974;34:1833. [PubMed] [Google Scholar]
  • 13.Han T, Takita H. Impaired lymphocyte response to allogeneic cultured lymphoid cells in patients with lung cancer. N Engl J Med. 1972;286:605. doi: 10.1056/nejm197203162861113. [DOI] [PubMed] [Google Scholar]
  • 14.Hogan TF, Borden EC, Freeberg BL, Vieau J, Hsieh F-Y, Crowley J. Enhancement in recall antigen responses by frequent, repetitive skin testing with candida, mumps, and streptokinase-streptodornase in 38 normal adults. Cancer Immunol Immunother. 1980;10:27. [Google Scholar]
  • 15.Israel L (1976) Nonspecific immunological alterations in patients with lung cancer. In: Israel L, Chahinian AP (eds) Lung cancer natural history, prognosis and therapy. Academic Press, pp 141–150
  • 16.Kopersztych S, Rezkallah MT, Miki SS, Naspitz CK, Mendes NF. Cell-mediated immunity in patients with carcinoma. Cancer. 1976;38:1149. doi: 10.1002/1097-0142(197609)38:3<1149::aid-cncr2820380316>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  • 17.Lehmann EL. Nonparametrics: Statistical methods based on ranks. San Francisco: Holden-Day; 1975. p. 12. [Google Scholar]
  • 18.Livingston RB. Combination chemotherapy of bronchogenic carcinoma. I. Non-oat cell. Cancer Treat Rev. 1977;4:153. doi: 10.1016/s0305-7372(77)80022-4. [DOI] [PubMed] [Google Scholar]
  • 19.Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163. [PubMed] [Google Scholar]
  • 20.McKneally MF, Maver CM, Kausel HW. Regional immunotherapy of lung cancer using postoperative intrapleural BCG. In: Terry WD, Windhorst D, editors. Immunotherapy of cancer: Present status of trials in man. New York: Raven Press; 1978. p. 161. [Google Scholar]
  • 21.Mikulski SM, McGuire WP, Louie AC, Chirigos MA, Muggia FM. Immunotherapy of lung cancer. I. Review of clinical trials in non-small cell histologic types. Cancer Treat Rev. 1979;6:177. doi: 10.1016/s0305-7372(79)80069-9. [DOI] [PubMed] [Google Scholar]
  • 22.Prentice RL. Linear rank tests with right censored data. Biometrika. 1978;65:167. [Google Scholar]
  • 23.Pross HF, Baines MG. Spontaneous human lymphocyte-mediated cytotoxicity against tumour target cells. I. The effect of malignant disease. Int J Cancer. 1976;18:593. doi: 10.1002/ijc.2910180508. [DOI] [PubMed] [Google Scholar]
  • 24.Rees JC, Rossio JL, Wilson HE, Minton JP, Dodd MC. Cellular immunity in neoplasia: Antigen and mitogen responses in patients with bronchiogenic carcinoma. Cancer. 1975;36:2010. doi: 10.1002/cncr.2820360913. [DOI] [PubMed] [Google Scholar]
  • 25.Steele R, Han T. Effects of radiochemotherapy and splenectomy on cellular immunity in long-term survivors of Hodgkin's disease and non-Hodgkin's lymphoma. Cancer. 1978;42:133. doi: 10.1002/1097-0142(197807)42:1<133::aid-cncr2820420123>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  • 26.Stratton ML, Herz J, Loeffler RA, McClurg FL, Reiter A, Bernstein P, Danley DL, Benjamin E. Antibody-dependent cell-mediated cytotoxicity in treated and nontreated cancer patients. Cancer. 1977;40:1045. doi: 10.1002/1097-0142(197709)40:3<1045::aid-cncr2820400312>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
  • 27.Takasugi M, Ramseyer A, Takasugi J. Decline of natural nonselective cell-mediated cytotoxicity in patients with tumor progression. Cancer Res. 1977;37:413. [PubMed] [Google Scholar]
  • 28.Weese JL, Oldham RK, Tormey DC, Barlock AL, Morales A, Cohen MH, West WH, Herberman RB, Alford TC, Shorb PE, Tsangaris NT, Cannon GB, Dean JH, Djeu J, McCoy JL. Immunologic monitoring in carcinoma of the breast. Surg Gynecol Obstet. 1977;145:209. [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES